Scynexis (United States)

Recent papers from Scynexis (United States)

1. Neural Spawning: Self-Growing Weather Models via Uncertainty-Triggered Specialist Birth with Independent Bayesian Self-Distillation2026
2. ClimyNet-Ω: A Dual-Brain Weather Architecture with Ten Novel Mathematical Power-Ups for Hyperlocal Personalized Forecasting2026
3. A phase 3, multicenter, randomized, placebo-controlled trial of monthly oral ibrexafungerp to reduce the incidence of recurrent vulvovaginal candidiasisAmerican Journal of Obstetrics and Gynecology · 2025
4. Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin BAntimicrobial Agents and Chemotherapy · 2024
5. Food and Drug Administration Public Workshop Summary—Development Considerations of Antifungal Drugs to Address Unmet Medical NeedClinical Infectious Diseases · 2023
6. Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold InfectionsJournal of Fungi · 2022
7. Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306Journal of Women s Health · 2022
8. In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European StudyFrontiers in Cellular and Infection Microbiology · 2022
9. DNDI-6148: A Novel Benzoxaborole Preclinical Candidate for the Treatment of Visceral LeishmaniasisJournal of Medicinal Chemistry · 2021
10. Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306)BJOG An International Journal of Obstetrics & Gynaecology · 2021
11. FDA Public Workshop Summary—Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal DrugsClinical Infectious Diseases · 2021
12. Identification of Clinical Candidate M2698, a Dual p70S6K and Akt Inhibitor, for Treatment of PAM Pathway-Altered CancersJournal of Medicinal Chemistry · 2021
13. Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal CandidiasisClinical Infectious Diseases · 2021
14. Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)Clinical Infectious Diseases · 2021
15. In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal CandidiasisAntimicrobial Agents and Chemotherapy · 2021
16. Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrataFrontiers in Cellular and Infection Microbiology · 2021
17. A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vivo Activity in a Murine Model of Hematogenously Disseminated Candida albicansAntimicrobial Agents and Chemotherapy · 2020
18. A Second-Generation Fungerp Analog, SCY-247, Shows Potent In Vitro Activity against Candida auris and Other Clinically Relevant Fungal IsolatesAntimicrobial Agents and Chemotherapy · 2020
19. Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris InfectionsSHILAP Revista de lepidopterología · 2020
20. Efficacy of Ibrexafungerp (SCY-078) against Candida auris in an In Vivo Guinea Pig Cutaneous Infection ModelAntimicrobial Agents and Chemotherapy · 2020